LQDALiquidia Corporation

$27.39+15% 1Y

$27.39

$21.8052 weeks$91.06

LQDA in its own filings

Nothing in LQDA's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

162

Events found in the filings · across 690 filings · the record starts in 2020

Hard flags: none
Hard flags
Most recent filing: Sep 30, 2026
Most recent filing · Form 8-K
Record starts: Aug 12, 2020
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 2, 2026
SEC comment-letter activity13 occurrences: 2025-03-21

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 30, 2026On September 30, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release regarding the litigation filed by United Therapeutics Corporation in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 and the Company’s lead …Other event · Form 8-K
Sep 3, 2026On September 3, 2026, Liquidia Corporation, a Delaware corporation (the “Company”), issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to YUTREPIA ® (treprostinil) inhalation powder for the treatment of Raynaud’s phenomenon associated with systemic sclerosis.Other event · Form 8-K
Aug 12, 2026On August 12, 2026, the Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Earnings release · Form 8-K
Jun 8, 2026On June 8, 2026, Liquidia Corporation, a Delaware corporation, issued a press release announcing that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.Other event · Form 8-K
May 11, 2026On May 11, 2026, the Company updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others.Earnings release · Form 8-K
Mar 5, 2026Liquidia Corporation Reports Fourth Quarter.Earnings release · press release
Jan 9, 2026Liquidia Corporation Announces Preliminary.Regulation FD disclosure · press release
Nov 3, 2025Liquidia Corporation Reports Third Quarter.Earnings release · press release
Oct 30, 2025On October 27, 2025 (the “Effective Date”), Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and a wholly owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into an exclusive licensing agreement (the “License Agreement”) with Vectura Limited, a …Material agreement entered · Form 8-K